VRNA vs. ORCL

Last updated Jun 9, 2026

VRNA (Verona Pharma plc) and ORCL (Oracle Corporation) are both stocks. VRNA operates in Biotechnology (Healthcare), while ORCL operates in Software - Infrastructure (Technology). At a 0.11 correlation, their price movements are largely independent.

Performance

VRNA vs. ORCL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verona Pharma plc (VRNA) and Oracle Corporation (ORCL). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

ORCL

• 1D: -0.87%
• 1M: 8.10%
• YTD: 9.34%
• 6M: -3.36%
• 1Y: 22.94%
• 3Y*: 25.94%
• 5Y*: 21.81%
• 10Y*: 20.30%

*Multi-year figures are annualized to reflect compound growth (CAGR)

VRNA vs. ORCL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%
ORCL Oracle Corporation	9.34%	18.13%	59.99%	30.94%	-4.65%	36.89%	24.25%	19.34%	-2.97%	6.61%

Correlation

The correlation between VRNA and ORCL is -0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.01
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (5Y) Calculated over the trailing 5-year period	0.12
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.11

The correlation between VRNA and ORCL shifts across timeframes, from -0.01 (1 year) to 0.13 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap VRNA : $9.72B ORCL : $617.24B
EPS VRNA : -$0.69 ORCL : $5.56
PS Ratio VRNA : 57.97 ORCL : 9.64
PB Ratio VRNA : 34.92 ORCL : 15.81
Total Revenue (TTM) VRNA : $167.65M ORCL : $64.08B
Gross Profit (TTM) VRNA : $159.52M ORCL : $58.10B
EBITDA (TTM) VRNA : -$40.86M ORCL : $17.85B

Return for Risk

VRNA vs. ORCL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ORCL

ORCL Risk / Return Rank: 54
ORCL Sharpe Ratio Rank: 55
ORCL Sortino Ratio Rank: 58
ORCL Omega Ratio Rank: 55
ORCL Calmar Ratio Rank: 52
ORCL Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRNA vs. ORCL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Oracle Corporation (ORCL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	VRNA	ORCL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.35	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.52	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.58	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.49	—

Drawdowns

Drawdown Indicators

	VRNA	ORCL	Difference
Max Drawdown Largest peak-to-trough decline	—	-84.19%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-58.25%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-58.25%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-58.25%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-58.25%	—
Current Drawdown Current decline from peak	—	-34.98%	—
Average Drawdown Average peak-to-trough decline	—	-29.10%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	35.04%	—

Volatility

Volatility by Period

	VRNA	ORCL	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	21.62%	—
Volatility (6M) Calculated over the trailing 6-month period	—	42.42%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	65.38%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	41.98%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	35.01%	—

Dividends

VRNA vs. ORCL - Dividend Comparison

VRNA has not paid dividends to shareholders, while ORCL's dividend yield for the trailing twelve months is around 0.94%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ORCL Oracle Corporation	0.94%	0.97%	0.96%	1.44%	1.57%	1.38%	1.48%	1.72%	1.68%	1.52%	1.56%	1.56%
VRNA Verona Pharma plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both VRNA and ORCL in my portfolio?

VRNA and ORCL have a correlation of -0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.